Medical Cannabis for epilepsy: The Dutch Announce astonishing €1.4 Million to Fund Research
October 1, 2021 by Cannabis Company

Medical Cannabis for epilepsy: The Dutch Announce astonishing €1.4 Million to Fund Research

The Dutch Ministry of Health has recently announced that a €1.4 million grant will be made available for research into the effectiveness of medical cannabis products in treating intractable epilepsy in children. This is a very large sum being put forward for an honourable cause.

The grant will be open to researchers who plan to conduct research relevant to whether medical marijuana products are able to reduce the frequency/severity of seizures in children with treatment-resistant epilepsy. Registration will be open until September 28, 2021.

person holding euro bills. Medical Cannabis for epilepsy: The Dutch Announce astonishing €1.4 Million to Fund Research

The grant is not the first step the Dutch government has taken. In fact, it comes as the second installment of the Dutch government's research funding into the potential of medical cannabis. Last year, an initial grant of €1.9 million was made available to help research medical cannabis for neuropathic pain.

The grants for research into childhood epilepsy would have come as a direct result of a question from the Dutch House of Representatives. Rep. Vera Bergkamp urged the government to "do short-term research … the effect of medical cannabis [on] children with epilepsy."

Successful candidates must use medical cannabis from the Office of Medicinal Cannabis (WTO) for their research. Revenue from medical cannabis sold by the WTO, both in the Netherlands and abroad, was used to fund both rounds of grants.

There is little scientific evidence that medicinal cannabis can act as a seizure suppressant in epilepsy patients, no matter how many individuals claim that marijuana stopped their seizures. The Drug Enforcement Administration requires that research in marijuana be conducted by researchers who apply for a special license from them. The National Institute for Drug Abuse (NIDA) of the U.S must be granted permission in order to gain access to its supply of drugs. Research has been impacted by these challenges.

Since 1970 however, not a lot of studies have been conducted in the U.S. to assess this item's safety. But there have been other studies of medicinal cannabis from around the world, even some that are still currently under research.

woman leans on wall in white fur jacket docking her head while holding it using her leaf hand. Medical cannabis can be good for epilepsy attacks.

The study found that tetrahydrocannabinol (THC), the active ingredient in medicinal cannabis most likely responsible for its widespread popularity, is just one of a group of chemical compounds that cause medicinal effects. One such molecule is cannabidiol (CBD), medicinal cannabis which does not produce the same sort of rush as marijuana does. As a medicinal compound, CBD is quickly become known as one of the most promising compounds of the cannabis plant.

Taking into consideration the results of these initial studies, there are currently a number of studies taking place in the US and other countries that are proceeding to test whether CBD in a drug formulation will help control seizures, a medicinal cannabis does that.

Medical cannabis in treatment-resistant epilepsy

Clinical evidence has increasingly demonstrated the potential of cannabis compounds for the treatment of various conditions. One of the most compelling areas of research so far has been the treatment of rare forms of treatment-resistant epilepsy - particularly in children and adolescents.

Current findings suggest important properties possessed by CBD (cannabidiol), which is a common non-psychoactive cannabinoid found in the cannabis plant. In fact, CBD may be effective in reducing the frequency and severity of epileptic seizures.

Dutch pharmacy CBD-based medical marijuana products can currently be prescribed for children (2 to 18 years old) with Dravet syndrome or patients aged two years and older with Lennox Gastaut syndrome - both rare forms of treatment-resistant epilepsy. The drug (Bedrolite) is manufactured by the Dutch pharmaceutical company Bedrocan.

Patients in the UK can also be prescribed medical cannabis for the treatment of intractable epilepsy, although patients remain largely dependent on the private sector.

person holding clear glass bottle, doing research for medical cannabis.

Did you learn about Medical Cannabis for epilepsy? You can check some other of our health posts right here:

Happy woman stretching
TOPIC

SIGN UP

Get daily updates
Sign up with your email address to receive news and updates.
Cannabis Company
Silvia is a freelance writer and medical cannabis activist who lives in Tacoma. When she’s not writing about cannabis or working to bring a better medical cannabis system to Washington, she likes to DJ, play adaptive sports and volunteer in his Tacoma community. She supports national legalization and the opening up of the medical cannabis market in all 50 states.
back to all posts
| March 10, 2022
Cannabis market is one of the most job-generating industries in 2022
Cannabis market is one of the most job-generating industries in 2022
<< read more
| March 10, 2022
Hemp protein: what are the benefits?
Hemp Protein: What are the benefits?
<< read more
| March 10, 2022
CBD in sport: Brazilian triathlete becomes 1st to take part in innovative study
CBD in sport: Brazilian triathlete becomes 1st to take part in innovative study
<< read more
1 2 3 36
DIRECTORY
ARTICLES

Programs

Women Techmakets
Agency Program
Startup Launchpad

Programs

Phone
Name
Email

canna & co

cannabis company

Links

Magazine
Blog
Shop

Contact

Phone
Adrdress
Email
CANNA & CO, 2021 © All Rights Reserved | Desing by Tank Studio Lab
Political privacy | Terms & Conditions